MSMeiping Shen

Meiping Shen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meiping Shen has a total of 33 co-authors. Here are the top co-authors by number of shared publications:

  • Jingsheng Cai

    Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University 1

    9 shared publications
  • Yan Si

    Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University 1

    9 shared publications
  • Houchao Tong

    Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University 1

    8 shared publications
  • Hao Zhang

    Department of General Surgery, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China

    6 shared publications
  • Xi Zhuang

    Department of General Surgery, Yixing People’s Hospital, Yixing, China

    6 shared publications
  • Yu Ding

    Department of Thyroid and Breast Surgery, Changzhou No. 2 People’s Hospital Affiliated to Nanjing Medical University, Changzhou, China

    6 shared publications

Latest Publications

  • MIB2-mediated ubiquitination of HK2 inhibits glycolysis in PTC

    by Lijun Zhang, Houchao Tong, Chengyuan Li, Jianing Zhou, Jingsheng Cai, Haisheng Fang, Jianfei Wen, Xiang Zhang, Heda Zhang, Meiping Shen, et al.

    Papillary thyroid carcinoma (PTC), the most common endocrine malignancy, frequently exhibits invasive behaviors, including tumor invasion and cervical lymph node metastasis, which serve as major determinants of prognosis. However, reliable predictive biomarkers for these aggressive features remain elusive. This study systematically elucidates the tumor-suppressive role of MIB E3 ubiquitin protein ligase 2 (MIB2) in PTC and delineates its underlying molecular mechanism. Integrated bioinformatics analysis and validation in clinical specimens demonstrated significant downregulation of MIB2 in PTC tissues relative to normal thyroid counterparts, with reduced MIB2 expression strongly inversely correlated with aggressive clinicopathological parameters, including lymph node metastasis and extrathyroidal extension. Functional assays revealed that ectopic MIB2 expression markedly attenuated PTC cell proliferation, migration, and invasion in vitro and tumorigenicity in vivo, whereas MIB2 knockdown exacerbated these malignant phenotypes. Mechanistically, MIB2 directly interacted with hexokinase 2 (HK2) via its RING domain, thereby promoting K48-linked polyubiquitination and subsequent proteasomal degradation of HK2. This led to substantial suppression of HK2 protein levels, impairment of glycolytic flux, and consequent restriction of PTC cell aggressiveness. To our knowledge, this is the first demonstration that MIB2 functions as a key negative regulator of PTC invasiveness by targeting HK2 for K48-linked ubiquitination-dependent degradation, thereby modulating glycolytic metabolism. These findings establish MIB2 as a critical suppressor in PTC progression and highlight its potential as a diagnostic biomarker and therapeutic target for aggressive PTC, providing a foundation for the development of precision intervention strategies.

  • Open Access

    Sialylation in Thyroid Carcinoma: An Overview of Mechanisms, Markers, and Therapeutic Opportunities

    by Chengyuan Li, Jianing Zhou, Lijun Zhang, Yan Si, Xiang Zhang, Meiping Shen

    Thyroid carcinoma (TC) is the most prevalent malignancy of the endocrine system, with its incidence rising annually worldwide. Post-translational modifications and epigenetic changes have been documented to be pivotal in the initiation, progression, and malignant transformation of TC. In addition to mediating biological processes such as cell recognition, signal transduction, and immune regulation, these modifications can also significantly impact the development and metastasis of various cancers. Among these, sialylation is identified as a key post-translational modification, showing close associations with the invasiveness and metastatic potential of TC. This review aims to provide an overview of the current understanding of sialylation in TC, highlighting its underlying mechanisms and examining its roles in cell proliferation, invasion, and immune evasion. Additionally, this study intends to explore the potential of targeting sialylation as a novel therapeutic approach, providing new perspectives for TC prevention and treatment, as well as the development of new therapeutic agents.


  • UBE2T promotes papillary thyroid carcinoma progression by activating the JAK/STAT3 pathway via negative regulation of SOCS2

    by Lijun Zhang, Chengyuan Li, Jianing Zhou, Xiang Zhang, Haisheng Fang, Jingsheng Cai, Houchao Tong, Jianfei Wen, Heda Zhang, Meiping Shen, et al.


  • Genome-wide DNA methylation profiling reveals diagnostic markers in parathyroid tumours

    by Xiang Zhang, Ya Hu, Ming Cui, Yan Si, Meiping Shen, Quan Liao

  • Cell diversity and immune infiltration in the parathyroid tumour microenvironment

    by Xiang Zhang, Ya Hu, Ming Cui, Mengyi Wang, Xiaobin Li, Yalu Zhang, Sen Yang, Surong Hua, Meiping Shen, Quan Liao

    Tumour microenvironment has been recognized as a crucial factor influencing disease progression. However, relevant features and functions are insufficiently understood in parathyroid neoplasia. Single-cell RNA sequencing was performed to profile the transcriptome of 27,251 cells from 4 parathyroid adenoma (PA) tissue samples. External transcriptomic datasets and immunofluorescence staining of a tissue microarray were set for expression validation. Eight major cell types and various subpopulations were finely identified in PA. We found that a subcluster of tumour endocrine cells with low copy number variation probably presented as a resting state. Diverse infiltrating immune cell subtypes were identified, constructing an immunosuppressive microenvironment. Tumour-associated macrophages, which indicated an anti-inflammatory phenotype, were significantly increased in PA. Inflammatory tumour-associated fibroblasts (iTAFs) were newly verified and highlighted on the role of stromal-immune crosstalk. Positive correlation between iTAFs and increased CD163+ macrophages was uncovered. Moreover, CXCL12 receptor signalling is important for tumour angiogenesis and immune infiltration. Our findings provide a comprehensive landscape interpreting tumour cell heterogeneity, cell diversity, and immune regulation in parathyroid neoplasia. The valuable resources may promote the understanding of parathyroid tumour microenvironment.


  • Proactive exploration of inferior parathyroid gland using a novel meticulous thyrothymic ligament dissection technique

    by Xiaoting Wang, Yan Si, Jingsheng Cai, Hui Lu, Houchao Tong, Hao Zhang, Jianfei Wen, Meiping Shen


  • Open Access

    Long noncoding RNA FER1L4 promotes the malignant processes of papillary thyroid cancer by targeting the miR-612/ Cadherin 4 axis

    by Luyao Wu, Yu Ding, Houchao Tong, Xi Zhuang, Jingsheng Cai, Yan Si, Hao Zhang, Xiaoting Wang, Meiping Shen

    Background: Long noncoding RNAs (lncRNAs) have emerged as crucial regulators in various cancers. However, the functional roles of most lncRNA in papillary thyroid cancer (PTC) are not detailly understood. This study aims to investigate the biological function and molecular mechanism of lncRNA Fer-1 like family member 4 (FER1L4) in PTC.Methods: The expression of FER1L4 in PTC was determined via operating quantitative real-time PCR assays. Meanwhile, the clinical significance of FER1L4 in patients with PTC was described. The biological functions of FER1L4 on PTC cells were evaluated by gain and loss of function experiments. Moreover, animal experiments were performed to reveal the effect on tumor growth. Subcellular distribution of FER1L4 was determined by fluorescence in situ hybridization and subcellular localization assays. Luciferase reporter assay and RNA immunoprecipitation assay were applied to define the relationship between FER1L4, miR-612, and Cadherin 4 (CDH4).Results: Upregulated expression of FER1L4 in PTC tissues was positively correlated with lymph node metastasis (P = 0.020), extrathyroidal extension (P = 0.013) and advanced TNM stages (P = 0.013). In addition, knockdown of FER1L4 suppressed PTC cell proliferation, migration, and invasion, whereas ectopic expression of FER1L4 inversely promoted these processes. Mechanistically, FER1L4 could competitively bind with miR-612 to prevent the degradation of its target gene CDH4. This condition was further confirmed in the rescue assays.Conclusions: This study first demonstrates FER1L4 plays an oncogenic role in PTC via a FER1L4-miR-612-CDH4 axis and may provide new therapeutic and diagnostic targets for PTC.


  • Open Access

    Long Noncoding RNA FER1L4 Promotes the Malignant Processes of Papillary Thyroid Cancer by Targeting miR-612/ Cadherin 4 Axis

    by Luyao Wu, Yu Ding, Houchao Tong, Xi Zhuang, Jingsheng Cai, Yan Si, Hao Zhang, Xiaoting Wang, Meiping Shen

    Background: Long noncoding RNAs (lncRNAs) have emerged as crucial regulators in various cancers. However, the functional roles of most lncRNA in papillary thyroid cancer (PTC) are not detailly understood. This study aims to investigate the biological functions and molecular mechanisms of lncRNA Fer-1 like family member 4 (FER1L4) in PTC.Methods: The expression of FER1L4 in PTC was determined via operating qRT-PCR assays. Meanwhile, the clinical significance of FER1L4 in PTC patients was described. The biological functions of FER1L4 on PTC cells were evaluated by gain and loss of function experiments. Moreover, animal experiments were performed to reveal the effect on tumor growth. Subcellular distribution of FER1L4 was determined by fluorescence in situ hybridization and subcellular localization assays. Luciferase reporter assay and RNA immunoprecipitation assay were applied to define the relationship between FER1L4, miR-612, and Cadherin 4 (CDH4). Results: Upregulated expression of FER1L4 in PTC tissues was positively correlated with lymph node metastasis (P = 0.020), extrathyroidal extension (P = 0.013) and advanced TNM stages (P = 0.013). In addition, knockdown of FER1L4 suppressed PTC cell proliferation, migration and invasion, whereas ectopic expression of FER1L4 inversely promoted these processes. Mechanistically, FER1L4 could competitively bind with miR-612 to prevent the degradation of its target gene CDH4. This condition was further confirmed in the rescue assays.Conclusions: This study first demonstrates FER1L4 plays an oncogenic role in PTC via a FER1L4-miR-612-CDH4 axis and may provide new therapeutic and diagnostic targets for PTC.

  • Open Access

    The direct miR‐874‐3p‐target FAM84A promotes tumor development in papillary thyroid cancer

    by Yu Ding, Luyao Wu, Xi Zhuang, Jingsheng Cai, Houchao Tong, Yan Si, Hao Zhang, Xiaoting Wang, Meiping Shen

    With the improvement in diagnostic technology, the incidence of thyroid cancer (TC) is on the rise. Papillary thyroid carcinoma (PTC) is the most common pathological type of thyroid cancer; therefore, it is important to explore some valuable molecular targets to improve the treatment and prognosis of PTC. Studies have shown that family with sequence similarity 84, member A (FAM84A) is involved in the development of various tumors. However, the role of FAM84A in PTC remains unknown. Herein, we explored the biological function and specific molecular mechanism of FAM84A in PTC. Results indicated that FAM84A was upregulated in PTC tissues and cells. In addition, patients with higher FAM84A expression tended to possess larger tumor size, higher lymph node metastasis rate, and advanced TNM stage. Further studies indicated that downregulation of FAM84A could inhibit the development of PTC in vitro and in vivo by repressing the epithelial–mesenchymal transition (EMT) and Wnt/β‐catenin signaling pathway. Moreover, FAM84A was confirmed to be negatively regulated by tumor suppressor miR‐874‐3p. In conclusion, our findings suggest that FAM84A may act as a potential diagnostic and therapeutic target for PTC.


  • Open Access

    Long Noncoding RNA FER1L4 Promotes Papillary Thyroid Cancer Progression by Targeting miR-612/CDH4 Axis

    by Luyao Wu, Yu Ding, Xi Zhuang, Jingsheng Cai, Houchao Tong, Yan Si, Hao Zhang, Xiaoting Wang, Meiping Shen

    Background: Long noncoding RNAs (lncRNAs) have emerged as crucial regulators in various cancers. However, the functional roles of most lncRNA in papillary thyroid cancer (PTC) are not detailly understood. This study aims to investigate the biological functions and the molecular mechanism of lncRNA FER1L4 in PTC.Methods: The expression of FER1L4 in PTC was determined via operating RT-PCR assays. Meanwhile, the clinical significance of FER1L4 in PTC patients was described. The biological functions of FER1L4 on PTC cells were evaluated by gain and loss of function experiments. Moreover, animal experiments were performed to reveal the effect on tumor growth. Subcellular distribution of FER1L4 was determined by fluorescence in situ hybridization and subcellular localization assays. Luciferase reporter assay and RNA immunoprecipitation assay were applied to define the relationship between FER1L4, miR-612, and CDH4. Results: Upregulated expression of FER1L4 in PTC tissues was correlated with higher lymph node metastasis rate (p=0.020), extrathyroidal extension (p=0.013), and advanced TNM stage (p=0.013). In addition, knockdown of FER1L4 suppressed PTC cell proliferation, migration and invasion, whereas ectopic expression of FER1L4 inversely promoted these processes. Mechanistically, FER1L4 could competitively bind with miR-612 to prevent the degradation of its target gene Cadherin 4 (CDH4). This condition was further confirmed in the rescue assays.Conclusions: This study firstly demonstrates FER1L4 plays an oncogenic role in PTC via FER1L4-miR-612-CDH4 axis and may provide a new therapeutic and diagnostic target for PTC.